Clinical Trials Browser

Phase 2 × Hematopoietic Stem Cell Mobilization × 90 days × Clear all

NCT02441686 2026-01-13

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Phase 2 Completed

46 enrolled 13 charts

Multiple Myeloma